Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Amgen
Institute of Hematology & Blood Diseases Hospital, China
Brooke Army Medical Center
Dr Cipto Mangunkusumo General Hospital
University Hospital, Angers
Vifor Pharma
Polish Lymphoma Research Group
Mercy Health Ohio
Hoffmann-La Roche
University of Texas Southwestern Medical Center
University of Miami
Hoffmann-La Roche
Vanderbilt University Medical Center